drugset / Trial / NCT00743769
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether the intravenous administration of single- and multiple-ascending doses of Thymosin Beta 4 is safe and tolerable in healthy volunteers.
Timeline
- Start
- 2008-04
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
Outcome
Outcome not reported
Stopped: “Study never initiated due to contract manufacturing issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Thymosin Beta 4 | Peptide | 42 mg | Intravenous |
| Comparator | Thymosin Beta 4 | Peptide | 140 mg | Intravenous |
| Comparator | Thymosin Beta 4 | Peptide | 420 mg | Intravenous |
| Comparator | Thymosin Beta 4 | Peptide | 1260 mg | Intravenous |